Explain this page
Arphra AIPlain-English read on Eli Lilly and Company’s valuationAI Issuer Brief
Arphra AILoading cached brief…
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.09% | +0.90% | +12.31% | +2.85% | +2.28% | +0.68% | +44.82% | +147.88% | +445.29% | +1343.77% | +38403.91% |
Aftermarket
LiveLast trade
$1081.24
1 sh
Bid
$1078.58
80 sh
Ask
$1081.40
1 sh
Spread
$2.820
Sector & industry today
LiveSectors
- Technology+3.30%
- Basic Materials+0.98%
- Energy+0.83%
- Consumer Cyclical+0.49%
- Industrials+0.25%
- Communication Services+0.13%
- Healthcare-0.65%
- Financial Services-0.80%
- Consumer Defensive-0.84%
- Utilities-1.15%
- Real Estate-1.32%
Top industries (issuer's industry highlighted)
- Drug Manufacturers - General-1.11%
- Computer Hardware+8.35%
- Software - Infrastructure+7.61%
- Consulting Services+5.28%
- Coal+5.20%
- Manufacturing - Metal Fabrication+4.24%
- Staffing & Employment Services+4.08%
- Gambling, Resorts & Casinos+3.71%
- Broadcasting+3.70%
- Integrated Freight & Logistics+3.68%
- REIT - Healthcare Facilities-3.49%
- Software - Application+3.44%
Fair value
Football field →Weighted blend
$2,712.06
+150.66% vs spot
Recommendation
Strong Buy
17 of 19 methods
Method spread
2bull14bear
±5% threshold
Analyst PT consensus: $1,258.47 (+16.31%)
Total assets
$112.48B
Total debt
$42.5B
Cash & equiv
$7.16B
Operating CF
$16.81B
Free cash flow
$8.97B
Buybacks
-$4.11B
Analyst view
DB · price_targets + analyst_gradesConsensus target
$1,258.47
+16.31% upside
Low
$1,070.00
Median
$1,280.00
High
$1,350.00
Recent actions
0 ↑0 ↓8 hold
- May 01, 2026
- Apr 01, 2026
- Mar 01, 2026
- Feb 01, 2026
- Jan 01, 2026
News
DB · news_items- Eli Lilly launches Alzheimer's drug Donanemab in Indiareuters.com·May 13, 2026
- Lilly's Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy in two late-phase trialsprnewswire.com·May 12, 2026
- Lilly's Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy in two late-phase trialsprnewswire.com·May 12, 2026
- Is It Too Late to Buy Eli Lilly and Co (LLY) After 4.4% Rally? GF Value Says Undervaluedgurufocus.com·May 12, 2026
- In honor of its 150th anniversary, Eli Lilly and Company commits to support community organizations aiming to provide 500,000 meals and cold storage for 150 food pantriesgurufocus.com·May 12, 2026
- In honor of its 150th anniversary, Eli Lilly and Company commits to support community organizations aiming to provide 500,000 meals and cold storage for 150 food pantriesprnewswire.com·May 12, 2026
- In honor of its 150th anniversary, Eli Lilly and Company commits to support community organizations aiming to provide 500,000 meals and cold storage for 150 food pantriesprnewswire.com·May 12, 2026
- Eli Lilly Price Prediction: This Is Where The Stock Will End This Year247wallst.com·May 12, 2026
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q1 Mar 2026 | $19.8B | $7.4B | $8.26 |
| Q4 Dec 2025 | $19.29B | $6.64B | $7.39 |
| Q3 Sep 2025 | $17.6B | $5.58B | $6.21 |
| Q2 Jun 2025 | $15.56B | $5.66B | $6.29 |
| Q1 Mar 2025 | $12.73B | $2.76B | $3.06 |
| Q4 Dec 2024 | $13.53B | $4.41B | $4.88 |
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
LILLY ENDOWMENT INC other: Former 10% Shareholder | Sell | 2,208 | $2.2M | May 06, 2026 |
LILLY ENDOWMENT INC other: Former 10% Shareholder | Sell | 13,620 | $13.55M | May 06, 2026 |
LILLY ENDOWMENT INC 10 percent owner | Sell | 1,070 | $1.16M | Jan 07, 2026 |
LILLY ENDOWMENT INC 10 percent owner | Sell | 1,322 | $1.45M | Jan 07, 2026 |
LILLY ENDOWMENT INC 10 percent owner | Sell | 895 | $971.17K | Jan 07, 2026 |
LILLY ENDOWMENT INC 10 percent owner | Sell | 930 | $1.01M | Jan 07, 2026 |
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|---|---|---|---|---|
| FY 2025 | $65.18B | $29.7B | $20.64B | $22.95 | +31.66% |
| FY 2024 | $45.04B | $17.5B | $10.59B | $11.71 | +23.51% |
| FY 2023 | $34.12B | $10.79B | $5.24B | $5.80 | +15.36% |
| FY 2022 | $28.54B | $8.65B | $6.24B | $6.57 | +21.88% |
| FY 2021 | $28.32B | $7.93B | $5.58B | $5.85 | +19.71% |